Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. - Wikidata - wikimedia - TriplyDB

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

http://www.wikidata.org/entity/Q39770397

about

RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells Integrins as Therapeutic Targets for Respiratory Diseases SB-273005, an antagonist of αvβ3 integrin, reduces the production of Th2 cells and cytokine IL-10 in pregnant mice.RGD surface functionalization of the hydrophilic acrylic intraocular lens material to control posterior capsular opacification.First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting Prostaglandins in cancer cell adhesion, migration, and invasion Emerging insights into the molecular and cellular basis of glioblastoma.Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy Antiangiogenic therapy for glioma.Role of β1 integrin in tissue homing of neutrophils during sepsis.Cyclic-RGD peptides increase the adenoviral transduction of human mesenchymal stem cells.The role of PET/CT in cervical cancer The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.A novel treatment for glioblastoma: integrin inhibition.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Integrin modulators: a patent review.Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments.Angiogenesis in cancer: Anti-VEGF escape mechanisms Longitudinal expression analysis of αv integrins in human gliomas reveals upregulation of integrin αvβ3 as a negative prognostic factor.RGD-mediated delivery of small-molecule drugs.Molecular insights into melanoma brain metastases.Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.Exploring the Role of RGD-Recognizing Integrins in Cancer.Targeted therapy for glioma using cyclic RGD-entrapped polyionic complex nanomicelles.Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.Treatment options in newly diagnosed glioblastoma.Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.Venom-based peptide therapy: insights into anti-cancer mechanism.Re-thinking the preclinical development of GBM therapeutics.

P2860

Q28543148-E7EB80DF-E2FC-45C0-94F0-F648F0B04B11 Q33668635-44C73128-61DC-459D-80A6-075B951E15D1 Q33706286-1DB1E712-CCBB-4203-82BE-331C18EADA8C Q35514076-F238F538-9FEA-48B9-81B0-9581CDFCD950 Q35589741-C0FAFD57-96CA-436F-8769-7C91EB954474 Q35821653-09277DB0-2E22-4DE7-9BEA-6B376CA23D5F Q35914897-5E4098EE-DD7B-4C97-A685-A0CC81611E29 Q36062996-7374CF82-80CE-4F28-B4CD-6F4F49CBDE27 Q36065096-C24A07B5-E596-4B59-AEA0-CD42D4CC3234 Q36101999-6D0EC7D6-E1E4-4E2D-9D08-DE9C9A068DB3 Q36173771-45662DA2-E86E-457F-827A-445EED590460 Q36587726-5E8A6D94-8A9A-4719-ADE8-31B1DDB97E78 Q36637204-1C209796-D60E-44A9-94F7-D066FE276336 Q36697070-1F2E5AE3-DBA0-4C9A-B8F0-83D43012A69E Q36738745-C97452E1-770D-4548-9DB1-8DBAFDFBF827 Q36849213-9F5DFE55-1F44-4DF1-BF62-E63DE5EA3490 Q37526270-243DB9BC-85A3-42E4-87CE-DC6FBB792774 Q37997092-55159343-F439-4058-A6DD-62DC5362B1C6 Q38108186-0662F47E-A756-4186-BF5F-2B3020594C41 Q38139612-C0A0BFF0-E1F9-43DA-ABD2-CA182F90C232 Q38155932-CB023E5F-3E6E-4289-B059-3EC53E82E3C8 Q38389975-E8A72A41-F1FE-4EFB-AF53-4CCC82D8A238 Q38398188-43FA0876-7285-4728-956A-B5A989B5F919 Q38732486-3E579C4D-276E-4E72-B0DD-849041E2DFC5 Q38764364-1B684C29-2578-4363-9E48-299AD4C44F90 Q38950364-99E8D87D-F2B6-4A38-A796-8977DBDA914F Q40147550-F768AC69-D642-434E-AF4C-963A2075FC3F Q41670915-D1BECC73-893D-43DF-B39E-FAED9B4DE376 Q42139438-5299D848-A456-465C-A0D9-BDB42DF4F43E Q44362501-E2BB7F95-0069-48A0-A69E-E29F6155D518 Q44411444-4BF7298B-F370-4C6F-B66A-065CD4F14022 Q44532006-80AEBBDA-780E-4AA9-80DA-28AC5D178D2D Q47600958-563C6546-2263-4FA7-B5C7-FD857DD3EFBA Q47893559-F3AF1A74-C419-49FA-BD03-D0F5F700CCB1 Q49215171-DD72297D-0E8D-4168-B4F2-07634C4FC56D Q54969651-C3D4009B-C66E-44C6-9302-F48CD7978217

P2860

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

http://www.wikidata.org/entity/Q39770397

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@en

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@nl

type

label

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@en

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@nl

prefLabel

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@en

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@nl

P1433

Q39770397-BE92BE2E-DA20-4FF7-8704-4E98AFB0F3E9

P1476

Q39770397-32DD402D-AB49-436C-8802-340531F0B259

P2093

Q39770397-48188368-40E7-422C-8D08-DEF60F38C20A

Q39770397-AAA0F2DF-8130-4E80-86CD-62157E318836

Q39770397-D7F3EDB9-9E05-4961-84F0-4FF6C61BDB27

Q39770397-DC20F154-9C94-45E6-9E14-26425632E63F

P2860

Q39770397-01869A83-1FD2-41D0-9E24-6F794CAA03E7

Q39770397-0427B492-2D8E-489B-A10E-40B11BB2EA76

Q39770397-05450A78-E8A3-44AD-8405-A9150F207358

Q39770397-07741AF4-5B82-4CDC-9DDF-F3BF6E70882C

Q39770397-096235C1-8C20-4E73-959F-1B3A44DDC3A6

Q39770397-106832D6-AFF0-4674-812C-A88349361421

Q39770397-13159195-3BD7-4027-9E62-AF9C3E7BA8AB

Q39770397-1FEBA6EA-E374-4BFC-9635-B66727522B66

Q39770397-2952D591-5C03-4794-8387-B4ACEC95B30D

Q39770397-2C53D69B-E24A-43DF-8EC2-7D824853C59D

P304

Q39770397-A9082B03-A975-4FF9-9C28-13F2543CC3BF

P31

Q39770397-D1A4C0AC-091D-4648-A62D-7CFA08F0C754

P356

Q39770397-09B40AF8-D896-4078-B930-15ECA1967B00

P407

Q39770397-D0FE6844-D502-4DF2-AD9F-4FA787ED2AD8

P433

Q39770397-5FBDA1A0-4BD0-4CC5-8540-0B12B950B1CF

P478

Q39770397-CD4BBECA-5216-44B9-9BB4-840F9EDE81C9

P50

Q39770397-A940D67B-449F-4396-BABE-F1D298E0115F

Q39770397-F813E2C2-6BA6-48F0-8152-24EC793D3D55

P577

Q39770397-2B03DE16-34E4-4C17-B44B-F7D5C592741F

P698

Q39770397-CBC36218-2E49-4EEE-9555-1C9EF05C489A

P356

P1433

Future Oncology

P1476

Cilengitide: an RGD pentapepti ...... astoma and other malignancies.

@en

P2093

Bart Neyns

http://www.w3.org/2001/XMLSchema#string

Joerg Christian Tonn

http://www.w3.org/2001/XMLSchema#string

Louis Burt Nabors

http://www.w3.org/2001/XMLSchema#string

Roger Stupp

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Integrins in cancer: biological implications and therapeutic opportunities

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

P304

339-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.11.8

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

David A Reardon

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21417900

http://www.w3.org/2001/XMLSchema#string